eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer

Min Wu Chao, Li Ting Wang, Chin Yu Lai, Xiao Ming Yang, Ya Wen Cheng, Kuo Hsiung Lee, Shiow Lin Pan, Che Ming Teng

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

eIF4E binding protein 1 (4E-BP1), is critical for cap-dependent and cap-independent translation. This study is the first to demonstrate that 4E-BP1 expression correlates with colorectal cancer (CRC) progression. Compared to its expression in normal colon epithelial cells, 4E-BP1 was upregulated in CRC cell lines and was detected in patient tumor tissues. Furthermore, high 4E-BP1 expression was statistically associated with poor prognosis. Hypoxia has been considered as an obstacle for cancer therapeutics. Our previous data showed that YXM110, a cryptopleurine derivative, exhibited anticancer activity via 4E-BP1 depletion. Here, we investigated whether YXM110 could inhibit protein synthesis under hypoxia. 4E-BP1 expression was notably decreased by YXM110 under hypoxic conditions, implying that cap-independent translation could be suppressed by YXM110. Moreover, YXM110 repressed hypoxia-inducible factor 1a (HIF- 1α) expression, which resulted in decreased downstream vascular endothelial growth factor (VEGF) expression. These observations highlight 4E-BP1 as a useful biomarker and therapeutic target, indicating that YXM110 could be a potent CRC therapeutic drug.

Original languageEnglish
Pages (from-to)24092-24104
Number of pages13
JournalOncotarget
Volume6
Issue number27
DOIs
Publication statusPublished - 2015

Fingerprint

Colorectal Neoplasms
Carrier Proteins
Survival
Vascular Endothelial Growth Factor A
YXM110
Neoplasms
Colon
Therapeutics
Biomarkers
Epithelial Cells
Cell Line
Pharmaceutical Preparations
Hypoxia
Proteins

Keywords

  • Colorectal cancer (CRC)
  • EIF4E binding protein 1
  • Hypoxia
  • Prognosis
  • YXM110

ASJC Scopus subject areas

  • Oncology

Cite this

Chao, M. W., Wang, L. T., Lai, C. Y., Yang, X. M., Cheng, Y. W., Lee, K. H., ... Teng, C. M. (2015). eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer. Oncotarget, 6(27), 24092-24104. https://doi.org/10.18632/oncotarget.4483

eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer. / Chao, Min Wu; Wang, Li Ting; Lai, Chin Yu; Yang, Xiao Ming; Cheng, Ya Wen; Lee, Kuo Hsiung; Pan, Shiow Lin; Teng, Che Ming.

In: Oncotarget, Vol. 6, No. 27, 2015, p. 24092-24104.

Research output: Contribution to journalArticle

Chao, MW, Wang, LT, Lai, CY, Yang, XM, Cheng, YW, Lee, KH, Pan, SL & Teng, CM 2015, 'eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer', Oncotarget, vol. 6, no. 27, pp. 24092-24104. https://doi.org/10.18632/oncotarget.4483
Chao, Min Wu ; Wang, Li Ting ; Lai, Chin Yu ; Yang, Xiao Ming ; Cheng, Ya Wen ; Lee, Kuo Hsiung ; Pan, Shiow Lin ; Teng, Che Ming. / eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer. In: Oncotarget. 2015 ; Vol. 6, No. 27. pp. 24092-24104.
@article{ce6add2ef597489499f18ca952045909,
title = "eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer",
abstract = "eIF4E binding protein 1 (4E-BP1), is critical for cap-dependent and cap-independent translation. This study is the first to demonstrate that 4E-BP1 expression correlates with colorectal cancer (CRC) progression. Compared to its expression in normal colon epithelial cells, 4E-BP1 was upregulated in CRC cell lines and was detected in patient tumor tissues. Furthermore, high 4E-BP1 expression was statistically associated with poor prognosis. Hypoxia has been considered as an obstacle for cancer therapeutics. Our previous data showed that YXM110, a cryptopleurine derivative, exhibited anticancer activity via 4E-BP1 depletion. Here, we investigated whether YXM110 could inhibit protein synthesis under hypoxia. 4E-BP1 expression was notably decreased by YXM110 under hypoxic conditions, implying that cap-independent translation could be suppressed by YXM110. Moreover, YXM110 repressed hypoxia-inducible factor 1a (HIF- 1α) expression, which resulted in decreased downstream vascular endothelial growth factor (VEGF) expression. These observations highlight 4E-BP1 as a useful biomarker and therapeutic target, indicating that YXM110 could be a potent CRC therapeutic drug.",
keywords = "Colorectal cancer (CRC), EIF4E binding protein 1, Hypoxia, Prognosis, YXM110",
author = "Chao, {Min Wu} and Wang, {Li Ting} and Lai, {Chin Yu} and Yang, {Xiao Ming} and Cheng, {Ya Wen} and Lee, {Kuo Hsiung} and Pan, {Shiow Lin} and Teng, {Che Ming}",
year = "2015",
doi = "10.18632/oncotarget.4483",
language = "English",
volume = "6",
pages = "24092--24104",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "27",

}

TY - JOUR

T1 - eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer

AU - Chao, Min Wu

AU - Wang, Li Ting

AU - Lai, Chin Yu

AU - Yang, Xiao Ming

AU - Cheng, Ya Wen

AU - Lee, Kuo Hsiung

AU - Pan, Shiow Lin

AU - Teng, Che Ming

PY - 2015

Y1 - 2015

N2 - eIF4E binding protein 1 (4E-BP1), is critical for cap-dependent and cap-independent translation. This study is the first to demonstrate that 4E-BP1 expression correlates with colorectal cancer (CRC) progression. Compared to its expression in normal colon epithelial cells, 4E-BP1 was upregulated in CRC cell lines and was detected in patient tumor tissues. Furthermore, high 4E-BP1 expression was statistically associated with poor prognosis. Hypoxia has been considered as an obstacle for cancer therapeutics. Our previous data showed that YXM110, a cryptopleurine derivative, exhibited anticancer activity via 4E-BP1 depletion. Here, we investigated whether YXM110 could inhibit protein synthesis under hypoxia. 4E-BP1 expression was notably decreased by YXM110 under hypoxic conditions, implying that cap-independent translation could be suppressed by YXM110. Moreover, YXM110 repressed hypoxia-inducible factor 1a (HIF- 1α) expression, which resulted in decreased downstream vascular endothelial growth factor (VEGF) expression. These observations highlight 4E-BP1 as a useful biomarker and therapeutic target, indicating that YXM110 could be a potent CRC therapeutic drug.

AB - eIF4E binding protein 1 (4E-BP1), is critical for cap-dependent and cap-independent translation. This study is the first to demonstrate that 4E-BP1 expression correlates with colorectal cancer (CRC) progression. Compared to its expression in normal colon epithelial cells, 4E-BP1 was upregulated in CRC cell lines and was detected in patient tumor tissues. Furthermore, high 4E-BP1 expression was statistically associated with poor prognosis. Hypoxia has been considered as an obstacle for cancer therapeutics. Our previous data showed that YXM110, a cryptopleurine derivative, exhibited anticancer activity via 4E-BP1 depletion. Here, we investigated whether YXM110 could inhibit protein synthesis under hypoxia. 4E-BP1 expression was notably decreased by YXM110 under hypoxic conditions, implying that cap-independent translation could be suppressed by YXM110. Moreover, YXM110 repressed hypoxia-inducible factor 1a (HIF- 1α) expression, which resulted in decreased downstream vascular endothelial growth factor (VEGF) expression. These observations highlight 4E-BP1 as a useful biomarker and therapeutic target, indicating that YXM110 could be a potent CRC therapeutic drug.

KW - Colorectal cancer (CRC)

KW - EIF4E binding protein 1

KW - Hypoxia

KW - Prognosis

KW - YXM110

UR - http://www.scopus.com/inward/record.url?scp=84943423433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943423433&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4483

DO - 10.18632/oncotarget.4483

M3 - Article

C2 - 26204490

AN - SCOPUS:84943423433

VL - 6

SP - 24092

EP - 24104

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 27

ER -